Peter W. Feit - Concepedia

Author

Peter W. Feit

Leo Pharma (Denmark)

Also Known As

P. W. FEIT, P. W. Feit, P.W. Feit, PETER W. FEIT, Peter Feit, Peter W Feit, Peter W. Feit

Publications

Citations

H-Index

Concepts

All Affiliations

Leo Pharma (Denmark)University of Veterinary Medicine Hannover, Foundation University of Copenhagen University of Vienna University of Helsinki

About

Peter W. Feit is an author at Leo Pharma (Denmark) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	666
2	Natural Sciences	9	9	393
3	Biochemistry	7	7	502
4	Chemical Biology	2	2	93
5	Cellular Physiology	1	1	16

Peter W. Feit

Publications

891

Citations

H-Index

Page 1

	Year	Citations
cAMP-stimulated cation cotransport in avian erythrocytes: inhibition by "loop" diuretics H. Clive Palfrey, Peter W. Feit, Paul Greengard American Journal of Physiology-Cell Physiology 3-Aminobenzoic Acid DerivativesMammalian PhysiologyTransport SystemPharmacotherapyExperimental Pharmacology	1980	166
1,4-Bismethanesulfonates of the Stereoisomeric Butanetetraols and Related Compounds Peter W. Feit Journal of Medicinal Chemistry Pharmaceutical ScienceAltmetric Attention ScoreOrganic ChemistryChemistryChemical Derivative	1964	114
A novel prodrug‐based strategy to increase effects of bumetanide in epilepsy Kathrin Töllner, Claudia Brandt, Manuel Töpfer, Annals of Neurology	2014	100
Aminobenzoic acid diuretics. 2. 4-Substituted-3-amino-5-sulfamoylbenzoic acid derivatives Peter W. Feit Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceBioorganic ChemistryAminobenzoic Acid DiureticsBiochemistry	1971	82
Epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. Preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate Peter W. Feit, N. Rastrup‐Andersen, Rene Matagne Journal of Medicinal Chemistry Bioorganic ChemistryChemical AnalysisAltmetric Attention ScoreSecondary MetaboliteOrganic Chemistry	1970	72
The search for NKCC1-selective drugs for the treatment of epilepsy: Structure–function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A Kasper Lykke, Kathrin Töllner, Peter W. Feit, Epilepsy & Behavior Molecular PharmacologyNkcc1-selective DrugsVarious Bumetanide DerivativesStructure–function RelationshipMedicine	2016	43
Purification of proteins of the Na/Cl cotransporter from membranes of Ehrlich ascites cells using a bumetanide-sepharose affinity column Peter W. Feit, Else K. Hoffmann, Morten Schiødt, The Journal of Membrane Biology Protein SecretionBiochemistryNatural SciencesMembrane TransportMolecular Biology	1988	42
Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy Claudia Brandt, Patricia Seja, Kathrin Töllner, Neuropharmacology MedicineNeurotransmitterNeuropharmacologyNeurologyNeuroscience	2018	42
GLC Determination and Urinary Recovery of Bumetanide in Healthy Volunteers Peter W. Feit, K Roholt, Henrik Toft Sørensen Journal of Pharmaceutical Sciences Glc DeterminationUrologyMedicinePhysiologyClinical Pharmacology	1973	39
Aminobenzoic acid diuretics. 7. 3-Substituted 4-phenyl-, 4-arylcarbonyl-, and 4-arylmethyl-5-sulfamoylbenzoic acids and related compounds Ole B. Tvaermose Nielsen, Herta Bruun, Claus Bretting, Journal of Medicinal Chemistry	1975	23

Page 1